Preparation of Bifunctional Nanoparticles and Evaluation of Therapeutic Function in Glioma Cells.

Small interfering RNA (siRNA)drugs have great potential in the field of anti-tumor, but they have poor biological stability and are easily degraded by nucleases in vivo, resulting in poor bioavailability. In this study, a novel albumin Poly(lactide-co-glycolide) (PLGA) nanocarrier was prepared to efficiently deliver siRNA to glioma cells to achieve tumor-targeted therapy. Recombinant VAR2CSA protein (RVP) targeting albumin PLGA nanocarriers (RVP–APN–siRNA) loaded with EGFR-siRNA were prepared by a double emulsion method. Determine its characterization performance, loading rate, in vitro release and cell uptake, and investigate the effects of nanoparticles on the cytotoxicity, proliferation and apoptosis of brain glioma cells. The prepared nanoparticles are spherical with uniform particle size, the average particle size distribution is 120–180 nm, the average potential distribution is 20–30 mv, and the loading rate is 82.36 ± 1.84%. The release rate of siRNA within 24 h is 93%, with low cytotoxicity and targeting performance, effectively inhibiting the activity of glioma cells. The prepared albumin nanoparticles have good physical and chemical properties, and have dual functions of targeted recognition of glioma cells and tumor treatment. They are efficient and safe nano-carriers for tumor-targeted treatment, and have good potential in the application of siRNA-targeted drug delivery. [ABSTRACT FROM AUTHOR]